Cartesian Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug $(IND)$ application for a planned Phase 2 clinical trial of Descartes-08 in myositis. The trial, expected to begin in the first half of 2026, will evaluate the safety and efficacy of Descartes-08 in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome. This regulatory review enables Cartesian to proceed with a randomized, double-blind, placebo-controlled trial, with the possibility of a seamless transition to a pivotal study based on interim results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622906) on January 09, 2026, and is solely responsible for the information contained therein.